JPH09510709A - 多層調節放出性製薬学的投薬形態 - Google Patents
多層調節放出性製薬学的投薬形態Info
- Publication number
- JPH09510709A JPH09510709A JP7524706A JP52470695A JPH09510709A JP H09510709 A JPH09510709 A JP H09510709A JP 7524706 A JP7524706 A JP 7524706A JP 52470695 A JP52470695 A JP 52470695A JP H09510709 A JPH09510709 A JP H09510709A
- Authority
- JP
- Japan
- Prior art keywords
- layer
- dosage form
- drug
- active agent
- forming
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.複数の被覆粒子を含み、各粒子が: 水溶性活性薬剤でコーティング又は粒状化された不活性材料を含む芯; 水溶性フィルム形成性ポリマーのフィルム形成性混合物を含む、薬剤含有芯上 の第1のコーティング層; 被覆薬剤芯上で調節放出層を形成するフィルム形成性分散液又は溶液を含む、 第1のコーティング層上の第2のコーティング層; 水溶性フィルム形成性ポリマーを含む第3のコーティング層; 追加の水溶性活性薬剤を含む第4のコーティング層; 水溶性フィルム形成性ポリマーのフィルム形成性混合物を含む第5のコーティ ング層: 被覆薬剤芯上で調節放出層を形成するフィルム形成性分散液又は溶液を含む第 6のコーティング層;ならびに 水溶性フィルム形成性ポリマーの最後のコーティング層 を含む水溶性薬剤のための多層調節放出性製薬学的投薬形態。 2.水溶性フィルム形成性ポリマーのコーティング層の少なくとも1つがさらに 可塑剤を含む請求の範囲第1項の多層投薬形態。 3.さらに実質的即時放出を目的とする水溶性活性薬剤の外層を含む請求の範囲 第1項の多層投薬形態。 4.水溶性フィルム形成性ポリマーがヒドロキシプロピルメチルセルロース、ヒ ドロキシプロピルセルロース及びポビドンである請求の範囲第1項の多層投薬形 態。 5.可塑剤がポリエチレングリコールである請求の範囲第2項の多層投 薬形態。 6.調節放出層を形成するフィルム−形成性分散液が水ベースポリマーを含む請 求の範囲第1項の多層投薬形態。 7.水溶性活性薬剤がトラマドール、プソイドエフェドリン、フェニルプロパノ ールアミン及びそれらの塩類から成る群より選ばれる請求の範囲第1項の多層投 薬形態。 8.活性薬剤が非常に水溶性であり、トラマドールHCl又はプソイドエフェド リンHClである請求の範囲第1項の多層投薬形態。 9.活性薬剤がトラマドールHClである請求の範囲第1項の多層投薬形態。 10.第2及び第6のコーティング層の調節放出層が、約24時間にわたって実 質的に一定の活性薬剤の放出プロフィールを得る量で与えられる請求の範囲第1 項の多層投薬形態。 11.水ベースポリマーがエチルセルロースである請求の範囲第6項の多層投薬 形態。 12.調節放出層を形成するフィルム形成性分散液がさらにセバシン酸ジブチル 又はオレイン酸の少なくとも1つを含む請求の範囲第11項の多層投薬形態。 13.薬剤含有層のそれぞれに与えられる活性薬剤の合計量が約24時間にわた って活性薬剤の所望の血漿量を達成するように選択される請求の範囲第1項の多 層投薬形態。 14.それぞれ:順に第1の調節放出障壁層で上塗りされている活性薬剤芯;及 び追加の調節放出層で上塗りされている活性薬剤を含む少なくとも1層の追加の 層を含む複数の被覆粒子を含み、活性薬剤及びその各 コーティング層で用いられる調節放出障壁材料の量は、あらかじめ選択された2 0〜24時間にわたって患者における活性薬剤の所望の血漿量を得るのに有効な 量で与えられる、水溶性薬剤のための多層調節放出製薬学的投薬形態。 15.さらに即時放出を目的とする活性薬剤を含む外層を含む請求の範囲第14 項の多層投薬形態。 16.1層又はそれ以上の調節放出層及び活性薬剤を含む隣接層の間にはさまれ た少なくとも1層の水溶性フィルム形成性ポリマーの追加のコーティング層を含 む請求の範囲第11項の多層投薬形態。 17.複数の被覆粒子を含み、各粒子が: 水溶性活性薬剤でコーティング又は粒状化された不活性材料を含む芯; 有効フィルム形成量のヒドロキシプロピルメチルセルロース及び有効可塑剤量 のポリエチレングリコールの混合物を含む、薬剤含有芯上の第1のコーティング 層; 被覆薬剤芯上で調節放出層を形成するエチルセルロースを含む水ベースフィル ム形成性分散液を含む、第1のコーティング層上の第2のコーティング層; フィルム形成有効量のヒドロキシプロピルメチルセルロース及び可塑剤有効量 のポリエチレングリコールを含む第3のコーティング層; 追加の水溶性活性薬剤を含む第4のコーティング層; 有効フィルム形成量のヒドロキシプロピルメチルセルロース及び有効可塑剤量 のポリエチレングリコールの混合物を含む第5のコーティング層; 被覆薬剤芯上で調節放出層を形成するエチルセルロースを含む水ベースフィル ム形成性分散液を含む第6のコーティング層; フィルム形成有効量のヒドロキシプロピルメチルセルロース及び可塑剤有効量 のポリエチレングリコールを含む第7のコーティング層; 実質的即時放出を目的とする追加の水溶性活性薬剤を含む第8のコーティング 層;ならびに フィルム形成有効量のヒドロキシプロピルメチルセルロースポリマー及び可塑 剤有効量のポリエチレングリコールの最後のコーティング層 を含む水溶性薬剤のための多層調節放出製薬学的投薬形態。 18.活性薬剤が非常に水溶性であり、プソイドエフェドリンHClである請求 の範囲第17項の多層投薬形態。 19.活性薬剤がトラマドールHClである請求の範囲第17項の多層投薬形態 。 20.エチルセルロースの水ベースフィルム形成分散液がさらにセバシン酸ジブ チルを含む請求の範囲第17項の多層投薬形態。 21.活性薬剤含有芯を第1の調節放出障壁層で順に上塗りすることにより多層 調節放出投薬形態を製造し; 活性薬剤を含む少なくとも1層の追加の層を該第1の調節放出障壁層の上に設 け、それを追加の調節放出層により上塗りし;ここで活性薬剤及びそれぞれのそ のコーティング層で用いられる調節放出障壁材料の量は所望の時間にわたって患 者における活性薬剤の所望の血漿量を得るのに有効な量で与えられる 段階を含む、所望の時間にわたって患者において水溶性薬剤の所望の血漿量を得 るための方法。 22.さらに即時放出を目的とする活性薬剤を含む外層を含む請求の範囲第21 項の方法。 23.所望の時間が約20又は24時間である請求の範囲第21項の方法。 24.薬剤がトラマドールHCl又はプソイドエフェドリンHClである請求の 範囲第21項の方法。 25.順次のコーティングがすべて水性系において適用される請求の範囲第21 項の方法。 26.多層投薬形態が1層又はそれ以上の調節放出層及び活性薬剤を含む隣接層 の間にはさまれた少なくとも1層の水溶性フィルム形成性ポリマーの追加のコー ティング層を含む請求の範囲第21項の方法。 27.2種又はそれ以上の活性薬剤が投薬形態において与えられる請求の範囲第 21項の方法。 28.2種又はそれ以上の活性薬剤が1層又はそれ以上の薬剤層において与えら れる請求の範囲第1項の多層投薬形態。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/217,331 | 1994-03-23 | ||
US08/217,331 US5395626A (en) | 1994-03-23 | 1994-03-23 | Multilayered controlled release pharmaceutical dosage form |
PCT/US1995/003248 WO1995025506A1 (en) | 1994-03-23 | 1995-03-16 | Multilayered controlled release pharmaceutical dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH09510709A true JPH09510709A (ja) | 1997-10-28 |
JP4936577B2 JP4936577B2 (ja) | 2012-05-23 |
Family
ID=22810614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52470695A Expired - Lifetime JP4936577B2 (ja) | 1994-03-23 | 1995-03-16 | 多層調節放出性製薬学的投薬形態 |
Country Status (13)
Country | Link |
---|---|
US (2) | US5395626A (ja) |
EP (1) | EP0760655B1 (ja) |
JP (1) | JP4936577B2 (ja) |
AT (1) | ATE196250T1 (ja) |
AU (1) | AU703151B2 (ja) |
CA (1) | CA2185893C (ja) |
DE (1) | DE69518839T2 (ja) |
DK (1) | DK0760655T3 (ja) |
ES (1) | ES2151594T3 (ja) |
GR (1) | GR3034971T3 (ja) |
PT (1) | PT760655E (ja) |
WO (1) | WO1995025506A1 (ja) |
ZA (1) | ZA952343B (ja) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003509439A (ja) * | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
WO2007114376A1 (ja) * | 2006-03-30 | 2007-10-11 | Nippon Zoki Pharmaceutical Co., Ltd. | 固形医薬製剤 |
JP2010536770A (ja) * | 2007-08-13 | 2010-12-02 | アビューズ ディタレント ファーマスティカル エルエルシー | 乱用抵抗性医薬組成物、その使用方法および作製方法 |
JP2015522655A (ja) * | 2012-07-23 | 2015-08-06 | ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ | 3種の活性成分を含有する新規な時差放出医薬組成物 |
JP2019005032A (ja) * | 2017-06-22 | 2019-01-17 | 教裕 南郷 | 外皮内溶解型ニードル及びニードル装置 |
Families Citing this family (143)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6764697B1 (en) * | 1991-06-27 | 2004-07-20 | Alza Corporation | System for delaying drug delivery up to seven hours |
NZ260408A (en) * | 1993-05-10 | 1996-05-28 | Euro Celtique Sa | Controlled release preparation comprising tramadol |
US5891471A (en) * | 1993-11-23 | 1999-04-06 | Euro-Celtique, S.A. | Pharmaceutical multiparticulates |
KR100354702B1 (ko) * | 1993-11-23 | 2002-12-28 | 유로-셀티크 소시에떼 아노뉨 | 약학조성물의제조방법및서방형조성물 |
US5843480A (en) * | 1994-03-14 | 1998-12-01 | Euro-Celtique, S.A. | Controlled release diamorphine formulation |
US5645858A (en) * | 1994-10-06 | 1997-07-08 | Ortho Pharmaceutical Corporation | Multilayered controlled release pharmaceutical dosage form |
GB9422154D0 (en) | 1994-11-03 | 1994-12-21 | Euro Celtique Sa | Pharmaceutical compositions and method of producing the same |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
US5945125A (en) * | 1995-02-28 | 1999-08-31 | Temple University | Controlled release tablet |
TR199701323T1 (xx) * | 1995-05-09 | 1998-02-21 | Colorcon Limited | Farmas�tik alttabakalar�n elektrostatik olarak kaplanmas� i�in toz kaplama kompozisyonu. |
US7008668B2 (en) * | 1995-05-09 | 2006-03-07 | Phoqus Pharmaceuticals Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
US5783212A (en) * | 1996-02-02 | 1998-07-21 | Temple University--of the Commonwealth System of Higher Education | Controlled release drug delivery system |
EP0811374A1 (en) * | 1996-05-29 | 1997-12-10 | Pfizer Inc. | Combination dosage form comprising cetirizine and pseudoephedrine |
DE19630035A1 (de) * | 1996-07-25 | 1998-01-29 | Asta Medica Ag | Tramadol Multiple Unit Formulierungen |
US6238704B1 (en) * | 1996-09-13 | 2001-05-29 | Shionogi & Co., Ltd. | Sustained-release preparation utilizing thermal change and process for the production thereof |
SE9603667D0 (sv) * | 1996-10-08 | 1996-10-08 | Astra Ab | Pharmaceutical compositions |
US6919373B1 (en) | 1996-11-12 | 2005-07-19 | Alza Corporation | Methods and devices for providing prolonged drug therapy |
GB9623634D0 (en) * | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
US5788987A (en) * | 1997-01-29 | 1998-08-04 | Poli Industria Chimica Spa | Methods for treating early morning pathologies |
US6210710B1 (en) | 1997-04-28 | 2001-04-03 | Hercules Incorporated | Sustained release polymer blend for pharmaceutical applications |
US5840329A (en) * | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
US5885616A (en) * | 1997-08-18 | 1999-03-23 | Impax Pharmaceuticals, Inc. | Sustained release drug delivery system suitable for oral administration |
US6156342A (en) * | 1998-05-26 | 2000-12-05 | Andex Pharmaceuticals, Inc. | Controlled release oral dosage form |
US6602521B1 (en) | 1998-09-29 | 2003-08-05 | Impax Pharmaceuticals, Inc. | Multiplex drug delivery system suitable for oral administration |
DE29818454U1 (de) * | 1998-10-15 | 1999-01-14 | Euro Celtique Sa | Opioid-Analgetikum |
US6322819B1 (en) | 1998-10-21 | 2001-11-27 | Shire Laboratories, Inc. | Oral pulsed dose drug delivery system |
US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
DE19918325A1 (de) | 1999-04-22 | 2000-10-26 | Euro Celtique Sa | Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion |
US6555139B2 (en) | 1999-06-28 | 2003-04-29 | Wockhardt Europe Limited | Preparation of micron-size pharmaceutical particles by microfluidization |
US6245913B1 (en) | 1999-06-30 | 2001-06-12 | Wockhardt Europe Limited | Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole |
US6669954B2 (en) | 2000-01-25 | 2003-12-30 | John R. Crison | Controlled release of drugs |
US7220430B2 (en) | 2000-01-27 | 2007-05-22 | Tanabe Seiyaku Co., Ltd. | Sustained-release preparation and process for producing the same |
GB0002305D0 (en) * | 2000-02-01 | 2000-03-22 | Phoqus Limited | Power material for electrostatic application |
US6663891B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Erythromyacin antibiotic product, use and formulation thereof |
US6638532B2 (en) | 2000-02-24 | 2003-10-28 | Advancis Pharmaceutical Corp. | Tetracycline—doxycycline antibiotic composition |
US6991807B2 (en) * | 2000-02-24 | 2006-01-31 | Advancis Pharmaceutical, Corp. | Antibiotic composition |
US7025989B2 (en) * | 2000-02-24 | 2006-04-11 | Advancis Pharmaceutical Corp. | Multiple-delayed released antibiotic product, use and formulation thereof |
US6544555B2 (en) * | 2000-02-24 | 2003-04-08 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
WO2001062195A1 (en) | 2000-02-24 | 2001-08-30 | Advancis Pharmaceutical Corporation | Antibiotic and antifungal compositions |
US6663890B2 (en) | 2000-02-24 | 2003-12-16 | Advancis Pharmaceutical Corp. | Metronidazole antibiotic product, use and formulation thereof |
US6623758B2 (en) * | 2000-02-24 | 2003-09-23 | Advancis Pharmaceutical Corp. | Cephalosporin-metronidazole antibiotic composition |
US6565882B2 (en) | 2000-02-24 | 2003-05-20 | Advancis Pharmaceutical Corp | Antibiotic composition with inhibitor |
US6610328B2 (en) | 2000-02-24 | 2003-08-26 | Advancis Pharmaceutical Corp. | Amoxicillin-clarithromycin antibiotic composition |
US6667042B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Fluroquinilone antibiotic product, use and formulation thereof |
US6632453B2 (en) | 2000-02-24 | 2003-10-14 | Advancis Pharmaceutical Corp. | Ciprofoxacin-metronidazole antibiotic composition |
US6730320B2 (en) | 2000-02-24 | 2004-05-04 | Advancis Pharmaceutical Corp. | Tetracycline antibiotic product, use and formulation thereof |
US6667057B2 (en) | 2000-02-24 | 2003-12-23 | Advancis Pharmaceutical Corp. | Levofloxacin antibiotic product, use and formulation thereof |
US6669948B2 (en) | 2000-02-24 | 2003-12-30 | Advancis Pharmaceutical Corp. | Antibiotic product, use and formulation thereof |
US6627222B2 (en) | 2000-02-24 | 2003-09-30 | Advancis Pharmaceutical Corp. | Amoxicillin-dicloxacillin antibiotic composition |
AR030557A1 (es) * | 2000-04-14 | 2003-08-27 | Jagotec Ag | Una tableta en multicapa de liberacion controlada y metodo de tratamiento |
CA2407154A1 (en) | 2000-04-27 | 2001-11-01 | Verion, Inc | Zero order release and temperature-controlled microcapsules and process for the preparation thereof |
US6955821B2 (en) * | 2000-04-28 | 2005-10-18 | Adams Laboratories, Inc. | Sustained release formulations of guaifenesin and additional drug ingredients |
US8012504B2 (en) * | 2000-04-28 | 2011-09-06 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
US7838032B2 (en) * | 2000-04-28 | 2010-11-23 | Reckitt Benckiser Inc. | Sustained release of guaifenesin |
US6372252B1 (en) | 2000-04-28 | 2002-04-16 | Adams Laboratories, Inc. | Guaifenesin sustained release formulation and tablets |
US7985420B2 (en) * | 2000-04-28 | 2011-07-26 | Reckitt Benckiser Inc. | Sustained release of guaifenesin combination drugs |
EP1190712B1 (en) * | 2000-09-22 | 2004-09-01 | SMB Technology | Oral once daily tramadol beads composition |
US20020068078A1 (en) * | 2000-10-13 | 2002-06-06 | Rudnic Edward M. | Antifungal product, use and formulation thereof |
US7105174B2 (en) * | 2000-10-13 | 2006-09-12 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-neoplastic product, use and formulation thereof |
US7157095B2 (en) * | 2000-10-13 | 2007-01-02 | Advancis Pharmaceutical Corporation | Multiple-delayed release antifungal product, use and formulation thereof |
US6541014B2 (en) * | 2000-10-13 | 2003-04-01 | Advancis Pharmaceutical Corp. | Antiviral product, use and formulation thereof |
US7074417B2 (en) * | 2000-10-13 | 2006-07-11 | Advancis Pharmaceutical Corporation | Multiple-delayed release anti-viral product, use and formulation thereof |
US20040122090A1 (en) * | 2001-12-07 | 2004-06-24 | Lipton Stuart A. | Methods for treating neuropsychiatric disorders with nmda receptor antagonists |
US20020197314A1 (en) | 2001-02-23 | 2002-12-26 | Rudnic Edward M. | Anti-fungal composition |
FR2821747B1 (fr) * | 2001-03-09 | 2004-07-02 | Ethypharm Lab Prod Ethiques | Suspension de telithromycine a gout masque |
MXPA03008293A (es) * | 2001-03-13 | 2003-12-11 | Penwest Pharmaceuticals Co | Formas de dosis cronoterapeuticas. |
CA2446738C (en) * | 2001-05-11 | 2012-05-29 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
US20030070584A1 (en) | 2001-05-15 | 2003-04-17 | Cynthia Gulian | Dip coating compositions containing cellulose ethers |
US8309118B2 (en) | 2001-09-28 | 2012-11-13 | Mcneil-Ppc, Inc. | Film forming compositions containing sucralose |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US7157102B1 (en) * | 2002-05-31 | 2007-01-02 | Biotek, Inc. | Multi-layered microcapsules and method of preparing same |
US7429619B2 (en) | 2002-08-02 | 2008-09-30 | Mcneil Consumer Healthcare | Polyacrylic film forming compositions |
US20050020613A1 (en) * | 2002-09-20 | 2005-01-27 | Alpharma, Inc. | Sustained release opioid formulations and method of use |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US20040114368A1 (en) * | 2002-12-13 | 2004-06-17 | Shyu Shing Jy | Light device having rotatable or movable view |
GB0229258D0 (en) * | 2002-12-16 | 2003-01-22 | Boots Healthcare Int Ltd | Medicinal compositions |
GB2402895B (en) * | 2003-06-18 | 2006-08-23 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
US8425936B2 (en) * | 2003-07-21 | 2013-04-23 | Shionogi Inc. | Antibiotic product, use and formulation thereof |
EP1648407A4 (en) * | 2003-07-21 | 2011-08-31 | Middlebrook Pharmaceuticals Inc | ANTIBIOTIC PRODUCT, CORRESPONDING USE AND FORMULATION |
WO2005009365A2 (en) * | 2003-07-21 | 2005-02-03 | Advancis Pharmaceutical Corporation | Antibiotic product, use and formulation thereof |
AU2004263130A1 (en) * | 2003-08-06 | 2005-02-17 | Nirmal Mulye | Pharmaceutical composition containing water soluble drug |
CA2535177A1 (en) * | 2003-08-11 | 2005-02-24 | Advancis Pharmaceutical Corporation | Robust pellet |
JP2007502294A (ja) | 2003-08-12 | 2007-02-08 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
WO2005023184A2 (en) * | 2003-08-29 | 2005-03-17 | Advancis Pharmaceuticals Corporation | Antibiotic product, use and formulation thereof |
JP2007513869A (ja) * | 2003-09-15 | 2007-05-31 | アドバンシス ファーマスーティカル コーポレイション | 抗生物質製剤、その使用法及び作成方法 |
JP2007505921A (ja) * | 2003-09-19 | 2007-03-15 | ペンウェスト ファーマシューティカルズ カンパニー | 遅延放出剤形 |
US20050118267A1 (en) * | 2003-09-19 | 2005-06-02 | Penwest Pharmaceuticals Co. | Chronotherapeutic dosage forms |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
WO2005062898A2 (en) * | 2003-12-24 | 2005-07-14 | Advancis Pharmaceutical Corporation | Enhanced absorption of modified release dosage forms |
GB0330171D0 (en) * | 2003-12-30 | 2004-02-04 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
GB0407312D0 (en) * | 2004-03-31 | 2004-05-05 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
ES2261006B1 (es) * | 2004-06-10 | 2007-11-01 | Laboratorios Rubio, S.A. | Pellet multicapa de liberacion controlada de metilfenidato. |
US8715727B2 (en) * | 2004-07-02 | 2014-05-06 | Shionogi Inc. | Tablet for pulsed delivery |
US20060165769A1 (en) * | 2004-09-30 | 2006-07-27 | Hyatt John A | Pharmaceutical formulations containing vitamin E TPGS molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations |
KR20070058540A (ko) * | 2004-10-01 | 2007-06-08 | 니폰 조키 세야쿠 가부시키가이샤 | 고형 의약제제 |
US20060073205A1 (en) * | 2004-10-04 | 2006-04-06 | Kotoe Ohta | Controlled release granules comprising porous silica core |
EP2343057A1 (en) | 2004-11-23 | 2011-07-13 | Neuromolecular Pharmaceuticals, Inc | Method and composition for administering an NMDA receptor antagonist to a subject |
US7619007B2 (en) | 2004-11-23 | 2009-11-17 | Adamas Pharmaceuticals, Inc. | Method and composition for administering an NMDA receptor antagonist to a subject |
EP2623099A1 (en) | 2004-11-24 | 2013-08-07 | Neuromolecular Pharmaceuticals, Inc | Composition and method for treating neurological disease |
GB0427455D0 (en) * | 2004-12-15 | 2005-01-19 | Jagotec Ag | Dosage forms |
KR101406456B1 (ko) | 2005-04-06 | 2014-06-20 | 아다마스 파마슈티칼스, 인코포레이티드 | Cns 장애의 치료를 위한 방법 및 조성물 |
ZA200711123B (en) | 2005-06-27 | 2009-08-26 | Biovail Lab Int Srl | Modified-release formulations of a bupropion salt |
US8778924B2 (en) * | 2006-12-04 | 2014-07-15 | Shionogi Inc. | Modified release amoxicillin products |
US8357394B2 (en) | 2005-12-08 | 2013-01-22 | Shionogi Inc. | Compositions and methods for improved efficacy of penicillin-type antibiotics |
CA2635313C (en) * | 2005-12-29 | 2013-12-31 | Osmotica Corp. | Triple combination release multi-layered tablet |
US20070190141A1 (en) * | 2006-02-16 | 2007-08-16 | Aaron Dely | Extended release opiate composition |
US8299052B2 (en) | 2006-05-05 | 2012-10-30 | Shionogi Inc. | Pharmaceutical compositions and methods for improved bacterial eradication |
US20070298105A1 (en) * | 2006-06-27 | 2007-12-27 | Hwang Stephen S | Methods of treating conditions by sustained release administration of benzimidazole derivatives |
CA2656191C (en) * | 2006-06-28 | 2015-12-08 | Surmodics, Inc. | Hydrophilic active agent eluting polymeric matrices with microparticles |
US20100008987A1 (en) * | 2006-08-21 | 2010-01-14 | Pasula Basavaiah Chowdary | Modified Release Pharmaceutical Composition of Bupropion Hydrochloride |
US8623397B2 (en) * | 2007-04-13 | 2014-01-07 | The Regents Of The University Of Michigan | Delivery device and method for forming the same |
US20090246276A1 (en) | 2008-01-28 | 2009-10-01 | Graham Jackson | Pharmaceutical Compositions |
US20110217371A1 (en) * | 2008-11-10 | 2011-09-08 | Amorepacific Corporation | Controlled-release microparticles and method of preparing same |
US20100233259A1 (en) * | 2008-12-12 | 2010-09-16 | Pascal Grenier | Dosage form of ropinirole |
US20100221328A1 (en) * | 2008-12-31 | 2010-09-02 | Wertz Christian F | Sustained-release formulations |
EP2488029B1 (en) | 2009-09-30 | 2016-03-23 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse |
CN102781259A (zh) | 2009-09-30 | 2012-11-14 | 加利福尼亚大学董事会 | 辅因子及个体使用方法 |
AU2010325960C1 (en) | 2009-12-02 | 2015-08-06 | Adamas Pharma, Llc | Amantadine compositions and methods of use |
KR101243938B1 (ko) * | 2010-10-19 | 2013-03-19 | 이희엽 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
KR20140054066A (ko) | 2011-07-15 | 2014-05-08 | 뉴서트 사이언시스, 인크. | 대사 경로 조절을 위한 조성물 및 방법 |
US9198454B2 (en) | 2012-03-08 | 2015-12-01 | Nusirt Sciences, Inc. | Compositions, methods, and kits for regulating energy metabolism |
SG10201709195TA (en) | 2012-11-13 | 2017-12-28 | Nusirt Sciences Inc | Compositions and methods for increasing energy metabolism |
CN104968333B (zh) | 2012-11-30 | 2018-07-10 | 阿库拉制药公司 | 活性药物成分的自调节释放 |
CN105101958B (zh) | 2013-01-15 | 2019-05-17 | 纽斯尔特科学公司 | 治疗肺病状 |
US10596127B2 (en) | 2013-03-14 | 2020-03-24 | Wellesley Pharmaceuticals, Llc | Composition for reducing the frequency of urination, method of making and use thereof |
JP6550370B2 (ja) | 2013-03-15 | 2019-07-24 | ニューサート サイエンシーズ, インコーポレイテッド | 脂質レベルを低下させるロイシンおよびニコチン酸 |
US20140275150A1 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
CA2939833A1 (en) | 2014-02-27 | 2015-09-03 | Nusirt Sciences, Inc. | Compositions and methods for the reduction or prevention of hepatic steatosis |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
CA2936741C (en) | 2014-10-31 | 2018-11-06 | Purdue Pharma | Methods and compositions particularly for treatment of attention deficit disorder |
CN105764509B (zh) * | 2014-11-03 | 2019-03-19 | 杭州领业医药科技有限公司 | 达比加群酯或其盐的投药制剂及其制备方法 |
WO2017040607A1 (en) | 2015-08-31 | 2017-03-09 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
JP2018529710A (ja) * | 2015-09-30 | 2018-10-11 | ウェルズリー ファーマスーティカルズ、エルエルシー | 排尿の頻度を低減するための組成物、ならびにその作製および使用方法 |
US11278506B2 (en) | 2015-10-09 | 2022-03-22 | Rb Health (Us) Llc | Pharmaceutical formulation |
WO2017117569A1 (en) | 2015-12-30 | 2017-07-06 | Adamas Pharmaceuticals, Inc. | Methods and compositions for the treatment of seizure-related disorders |
CN106176683B (zh) * | 2016-08-31 | 2019-04-16 | 贵州益康制药有限公司 | 一种盐酸曲马多缓释胶囊及其制备方法和用途 |
US9707217B1 (en) | 2017-02-03 | 2017-07-18 | Osmotica Kereskedelmi Es Szolgaltato Kft | Dose-dumping resistant controlled release dosage form |
WO2018200885A1 (en) | 2017-04-26 | 2018-11-01 | Neurocentria, Inc. | Magnesium compositions and methods of use |
WO2019087084A1 (en) | 2017-11-02 | 2019-05-09 | Eman Biodiscoveries Sd. Bhd. | Extract of orthosiphon stamineus, formulations, and uses thereof |
WO2020067887A1 (en) | 2018-09-24 | 2020-04-02 | Erasmus University Medical Center Rotterdam | Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses |
US10722473B2 (en) | 2018-11-19 | 2020-07-28 | Purdue Pharma L.P. | Methods and compositions particularly for treatment of attention deficit disorder |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5835110A (ja) * | 1981-08-28 | 1983-03-01 | Tetsuo Kato | 徐放性マイクロカプセル |
JPS5982311A (ja) * | 1982-11-04 | 1984-05-12 | Shionogi & Co Ltd | セフアレキシン持効性製剤 |
JPS5995214A (ja) * | 1982-11-01 | 1984-06-01 | メレル・ダウ・フア−マス−テイカルズ・インコ−ポレ−テツド | 活性成分の不均質分布をもつ持効性固体適量形式 |
JPS62226926A (ja) * | 1986-03-27 | 1987-10-05 | Teisan Seiyaku Kk | 持続性複合顆粒剤 |
JPS62240618A (ja) * | 1986-04-11 | 1987-10-21 | Otsuka Pharmaceut Co Ltd | 持続性製剤 |
JPS63319134A (ja) * | 1987-06-22 | 1988-12-27 | スリー エス.テクノロジーズ ベスローテン ベノートスハップ | 水供給用シ−ト |
JPH0269414A (ja) * | 1987-09-03 | 1990-03-08 | Air Prod And Chem Inc | 持続的制御放出パターンを有する生物活性物質コーティング剤 |
JPH04338324A (ja) * | 1991-05-13 | 1992-11-25 | Shionogi & Co Ltd | マルチリザ−バ−型徐放性顆粒剤およびその製法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB793808A (en) * | 1954-07-22 | 1958-04-23 | Frank Mario Bardani | Sustained action pill |
US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US4917899A (en) * | 1983-12-22 | 1990-04-17 | Elan Corporation Plc | Controlled absorption diltiazem formulation |
DE3403329A1 (de) * | 1984-02-01 | 1985-08-01 | Horst Dr. 4019 Monheim Zerbe | Pharmazeutisches produkt in form von pellets mit kontinuierlicher, verzoegerter wirkstoffabgabe |
US4826688A (en) * | 1985-11-13 | 1989-05-02 | 501 Elan Corporation PLC. | Controlled absorption pharmaceutical formulation |
IT1197316B (it) * | 1986-10-01 | 1988-11-30 | Proter Spa | Formulazione galenica ad uso orale di derivati della reina a lento rilascio per impiego terapeutico |
JP2643222B2 (ja) * | 1988-02-03 | 1997-08-20 | エーザイ株式会社 | 多重層顆粒 |
ATE114472T1 (de) * | 1989-09-21 | 1994-12-15 | American Cyanamid Co | System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe. |
NZ242806A (en) * | 1991-05-20 | 1994-01-26 | Marion Laboratories Inc | Multi-layered acid-containing coated drug beads. |
US5213811A (en) * | 1991-09-13 | 1993-05-25 | Sterling Drug Inc. | Oral sustained-release drug compositions |
US5229135A (en) * | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
US5407686A (en) * | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
-
1994
- 1994-03-23 US US08/217,331 patent/US5395626A/en not_active Expired - Lifetime
- 1994-10-06 US US08/319,186 patent/US5474786A/en not_active Expired - Lifetime
-
1995
- 1995-03-16 PT PT95913711T patent/PT760655E/pt unknown
- 1995-03-16 WO PCT/US1995/003248 patent/WO1995025506A1/en active Search and Examination
- 1995-03-16 AT AT95913711T patent/ATE196250T1/de active
- 1995-03-16 AU AU19995/95A patent/AU703151B2/en not_active Expired
- 1995-03-16 JP JP52470695A patent/JP4936577B2/ja not_active Expired - Lifetime
- 1995-03-16 CA CA002185893A patent/CA2185893C/en not_active Expired - Lifetime
- 1995-03-16 DE DE69518839T patent/DE69518839T2/de not_active Expired - Lifetime
- 1995-03-16 EP EP95913711A patent/EP0760655B1/en not_active Expired - Lifetime
- 1995-03-16 DK DK95913711T patent/DK0760655T3/da active
- 1995-03-16 ES ES95913711T patent/ES2151594T3/es not_active Expired - Lifetime
- 1995-03-22 ZA ZA952343A patent/ZA952343B/xx unknown
-
2000
- 2000-11-30 GR GR20000402674T patent/GR3034971T3/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5835110A (ja) * | 1981-08-28 | 1983-03-01 | Tetsuo Kato | 徐放性マイクロカプセル |
JPS5995214A (ja) * | 1982-11-01 | 1984-06-01 | メレル・ダウ・フア−マス−テイカルズ・インコ−ポレ−テツド | 活性成分の不均質分布をもつ持効性固体適量形式 |
JPS5982311A (ja) * | 1982-11-04 | 1984-05-12 | Shionogi & Co Ltd | セフアレキシン持効性製剤 |
JPS62226926A (ja) * | 1986-03-27 | 1987-10-05 | Teisan Seiyaku Kk | 持続性複合顆粒剤 |
JPS62240618A (ja) * | 1986-04-11 | 1987-10-21 | Otsuka Pharmaceut Co Ltd | 持続性製剤 |
JPS63319134A (ja) * | 1987-06-22 | 1988-12-27 | スリー エス.テクノロジーズ ベスローテン ベノートスハップ | 水供給用シ−ト |
JPH0269414A (ja) * | 1987-09-03 | 1990-03-08 | Air Prod And Chem Inc | 持続的制御放出パターンを有する生物活性物質コーティング剤 |
JPH04338324A (ja) * | 1991-05-13 | 1992-11-25 | Shionogi & Co Ltd | マルチリザ−バ−型徐放性顆粒剤およびその製法 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003509439A (ja) * | 1999-09-14 | 2003-03-11 | スミスクライン・ビーチャム・コーポレイション | 水性コーティングされたビーズレットの製法 |
WO2007114376A1 (ja) * | 2006-03-30 | 2007-10-11 | Nippon Zoki Pharmaceutical Co., Ltd. | 固形医薬製剤 |
JP5120652B2 (ja) * | 2006-03-30 | 2013-01-16 | 日本臓器製薬株式会社 | 固形医薬製剤 |
US8367107B2 (en) | 2006-03-30 | 2013-02-05 | Nippon Zoki Pharmaceutical Co., Ltd. | Solid pharmaceutical preparation |
JP2010536770A (ja) * | 2007-08-13 | 2010-12-02 | アビューズ ディタレント ファーマスティカル エルエルシー | 乱用抵抗性医薬組成物、その使用方法および作製方法 |
JP2015522655A (ja) * | 2012-07-23 | 2015-08-06 | ランドシュタイナー サイエンティフィック エッセ アー デ シー ヴイ | 3種の活性成分を含有する新規な時差放出医薬組成物 |
JP2019005032A (ja) * | 2017-06-22 | 2019-01-17 | 教裕 南郷 | 外皮内溶解型ニードル及びニードル装置 |
Also Published As
Publication number | Publication date |
---|---|
EP0760655B1 (en) | 2000-09-13 |
US5395626A (en) | 1995-03-07 |
CA2185893A1 (en) | 1995-09-28 |
US5474786A (en) | 1995-12-12 |
EP0760655A1 (en) | 1997-03-12 |
MX9604300A (es) | 1998-05-31 |
ES2151594T3 (es) | 2001-01-01 |
DK0760655T3 (da) | 2000-11-13 |
ATE196250T1 (de) | 2000-09-15 |
AU1999595A (en) | 1995-10-09 |
AU703151B2 (en) | 1999-03-18 |
PT760655E (pt) | 2000-12-29 |
WO1995025506A1 (en) | 1995-09-28 |
JP4936577B2 (ja) | 2012-05-23 |
DE69518839D1 (de) | 2000-10-19 |
CA2185893C (en) | 2009-05-26 |
GR3034971T3 (en) | 2001-02-28 |
DE69518839T2 (de) | 2001-02-22 |
ZA952343B (en) | 1996-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4936577B2 (ja) | 多層調節放出性製薬学的投薬形態 | |
US5645858A (en) | Multilayered controlled release pharmaceutical dosage form | |
JP3426230B2 (ja) | 複数層の制御放出処方剤 | |
US4927640A (en) | Controlled release beads having glass or silicon dioxide core | |
JP4991072B2 (ja) | 時限拍動性薬物送達システム | |
US5246714A (en) | Drug preparation | |
AU2002330211B2 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
CN103211779B (zh) | 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统 | |
US4728512A (en) | Formulations providing three distinct releases | |
US6663888B2 (en) | Pulsatile release histamine H2 antagonist dosage form | |
PL203828B1 (pl) | Układ dostarczania leku chlorowodorku metylofenidatu z kapsułek o zmodyfikowanym uwalnianiu oraz sposób wytwarzania układu | |
US7022342B2 (en) | Controlled release oral dosage form of beta-adrenergic blocking agents | |
AU2002330211A1 (en) | Timed, sustained release multi-particulate dosage forms of propranolol | |
JPH02289512A (ja) | 徐放性医薬製剤 | |
JPH0237327B2 (ja) | ||
JP4447166B2 (ja) | 硫酸モルヒネマイクロ顆粒剤、製法および医薬調製物 | |
JP3456211B2 (ja) | 持続性製剤 | |
WO2005016317A1 (en) | Process for manufacture of extended release pellets containing diltiazem hci | |
AU742231B2 (en) | Multilayered controlled release pharmaceutical dosage form | |
MXPA96004300A (en) | Multilayered controlled release pharmaceutical dosage form |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060919 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061219 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070219 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070316 |
|
A72 | Notification of change in name of applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A721 Effective date: 20080729 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20080729 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090414 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090714 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20090824 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090814 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20090914 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100108 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100302 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111216 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120221 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150302 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |